Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1997 Nov;41(11):2573–2575. doi: 10.1128/aac.41.11.2573

In vitro activities of an investigational quinolone, glycylcycline, glycopeptide, streptogramin, and oxazolidinone tested alone and in combinations against vancomycin-resistant Enterococcus faecium.

R C Mercier 1, S R Penzak 1, M J Rybak 1
PMCID: PMC164167  PMID: 9371372

Abstract

We evaluated the in vitro activities of clinafloxacin, CL331,002, LY333328, quinupristin dalfopristin, and eperezolid (formerly known as U-100,592) against four strains of enterococci. All regimens tested resulted in the growth inhibition of each isolate. Against the three clinafloxacin-susceptible strains, clinafloxacin tested alone was the most active treatment, decreasing the bacterial inoculum by more than 3 log10 CFU/ml after 24 h in time-kill curve studies.

Full Text

The Full Text of this article is available as a PDF (137.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arthur M., Courvalin P. Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob Agents Chemother. 1993 Aug;37(8):1563–1571. doi: 10.1128/aac.37.8.1563. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Burney S., Landman D., Quale J. M. Activity of clinafloxacin against multidrug-resistant Enterococcus faecium. Antimicrob Agents Chemother. 1994 Jul;38(7):1668–1670. doi: 10.1128/aac.38.7.1668. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bush L. M., Calmon J., Cherney C. L., Wendeler M., Pitsakis P., Poupard J., Levison M. E., Johnson C. C. High-level penicillin resistance among isolates of enterococci. Implications for treatment of enterococcal infections. Ann Intern Med. 1989 Apr 1;110(7):515–520. doi: 10.7326/0003-4819-110-7-515. [DOI] [PubMed] [Google Scholar]
  4. Caron F., Pestel M., Kitzis M. D., Lemeland J. F., Humbert G., Gutmann L. Comparison of different beta-lactam-glycopeptide-gentamicin combinations for an experimental endocarditis caused by a highly beta-lactam-resistant and highly glycopeptide-resistant isolate of Enterococcus faecium. J Infect Dis. 1995 Jan;171(1):106–112. doi: 10.1093/infdis/171.1.106. [DOI] [PubMed] [Google Scholar]
  5. Emori T. G., Gaynes R. P. An overview of nosocomial infections, including the role of the microbiology laboratory. Clin Microbiol Rev. 1993 Oct;6(4):428–442. doi: 10.1128/cmr.6.4.428. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Fraise A. P., Brenwald N., Andrews J. M., Wise R. In-vitro activity of two glycylcyclines against enterococci resistant to other agents. J Antimicrob Chemother. 1995 Jun;35(6):877–881. doi: 10.1093/jac/35.6.877. [DOI] [PubMed] [Google Scholar]
  7. Kaatz G. W., Seo S. M., Lamp K. C., Bailey E. M., Rybak M. J. CI-960, a new fluoroquinolone, for therapy of experimental ciprofloxacin-susceptible and -resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother. 1992 Jun;36(6):1192–1197. doi: 10.1128/aac.36.6.1192. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Kang S. L., Rybak M. J. Comparative in vitro activities of LY191145, a new glycopeptide, and vancomycin against Staphylococcus aureus and Staphylococcus-infected fibrin clots. Antimicrob Agents Chemother. 1995 Dec;39(12):2832–2834. doi: 10.1128/aac.39.12.2832. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Moellering R. C., Jr The Garrod Lecture. The enterococcus: a classic example of the impact of antimicrobial resistance on therapeutic options. J Antimicrob Chemother. 1991 Jul;28(1):1–12. doi: 10.1093/jac/28.1.1. [DOI] [PubMed] [Google Scholar]
  10. Nachamkin I., Axelrod P., Talbot G. H., Fischer S. H., Wennersten C. B., Moellering R. C., Jr, MacGregor R. R. Multiply high-level-aminoglycoside-resistant enterococci isolated from patients in a university hospital. J Clin Microbiol. 1988 Jul;26(7):1287–1291. doi: 10.1128/jcm.26.7.1287-1291.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Norrby S. R., Jonsson M. Comparative in vitro activity of PD 127,391, a new fluorinated 4-quinolone derivative. Antimicrob Agents Chemother. 1988 Aug;32(8):1278–1281. doi: 10.1128/aac.32.8.1278. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Quintiliani R., Jr, Evers S., Courvalin P. The vanB gene confers various levels of self-transferable resistance to vancomycin in enterococci. J Infect Dis. 1993 May;167(5):1220–1223. doi: 10.1093/infdis/167.5.1220. [DOI] [PubMed] [Google Scholar]
  13. Shlaes D. M., Bouvet A., Devine C., Shlaes J. H., al-Obeid S., Williamson R. Inducible, transferable resistance to vancomycin in Enterococcus faecalis A256. Antimicrob Agents Chemother. 1989 Feb;33(2):198–203. doi: 10.1128/aac.33.2.198. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Tack K. J., McGuire N. M., Eiseman I. A. Initial clinical experience with clinafloxacin in the treatment of serious infections. Drugs. 1995;49 (Suppl 2):488–491. doi: 10.2165/00003495-199500492-00145. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES